The study aimed at assessing the safety, tolerability and pharmacokinetics of a single administration of BL-1021 at doses between 10mg and 80mg.
The preliminary modeling of the pharmacokinetic data collected in this trial predicts that a once daily administration of BL-1021 at the dose levels assessed in the trial will enable reaching effective doses in patients.
BioLineRx CEO Kinneret Savitsky said they believe BL-1021 has the potential to provide improved efficacy without the side effects associated with many existing medications.
"We anticipate that the final results and analysis will confirm that BL-1021 has the competitive advantage of a once daily administration," Savitsky said.